Part 1: Evaluation of Pediatric Cannabis–Drug Interaction Reports
Abstract Data addressing safety concerns related to potential drug interactions between cannabis‐derived products and pharmaceutical medications in the pediatric population…
Richard D. Boyce
Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System
Abstract The increasing utilization of cannabis products combined with lack of data regarding potential cannabis–prescription drug interactions is concerning. This…
A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies
Abstract SIGNIFICANCE STATEMENT: The data and knowledge resulting from natural product–drug interaction (NPDI) studies is distributed across a variety of…